Congressman Asks Colleagues To Demand DEA Allow Psilocybin Treatment For Terminal Patients

Marijuana Moment
By Kyle JaegerDec 17, 2021, 12:48 pm310 pts
A congressman is asking his fellow lawmakers to join him in requesting that the Drug Enforcement Administration (DEA) allow terminally ill patients to use psilocybin as an investigational treatment without the fear of federal prosecution. A new Dear Colleague letter that’s being circulated by Rep. Earl…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Virginia Marijuana Commission Talks Taxes And Revenue As Lawmakers Again Consider Legalizing Recreational Sales 80

Trump’s Pick For Traffic Safety Agency Will ‘Double Down’ On Marijuana-Impaired Driving Warnings As More States Legalize 73

CBD Has Potential To Treat Alcohol Use Disorder By Reducing Withdrawal Symptoms And Lowering Relapse Risk, Federally Funded Study Finds 69

Licensed New York Cannabis Retailers File Lawsuit Against Office of Cannabis Management 67

Minnesota Announces Recipients of $1M CanRenew Cannabis Grant Funds 67

From Stigma to Science: The Role of Education in Cannabis Acceptance 61

Federal Appeals Court: Medical Cannabis Consumers Shouldn’t Lose Their 2nd Amendment Rights 53

Federal Appeals Court Gives Medical Marijuana Patients Who Want To Own Guns A Win 49

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.